Global On-body Drug Delivery Devices Market - 2024-2031

Global On-body Drug Delivery Devices Market - 2024-2031

The global on-body drug delivery devices market reached US$ 37.9 billion in 2023 and is expected to reach US$ 73.3 billion by 2031 growing with a CAGR of 8.6% during the forecast period 2024-2031.

On-body drug delivery devices are medical devices that are designed to be worn on the body to deliver medications directly to patients or other therapeutic substances to the site of action. These devices are designed to release drugs through the skin, mucous membranes, or other body surfaces, providing a controlled and targeted delivery of medication.

These devices include various forms such as patches, pumps, and injectors, which can be attached to the body either under or over clothing. The primary purpose of these devices is to provide sustained and controlled delivery of medications, allowing for precise dosing at predetermined times or continuous infusion.

The on-body drug delivery device for the subcutaneous administration of small-molecule drugs is available for volumes up to 3 ml. It is patched onto the body. Typical applications are bolus and basal regimens over several hours. This patched-on device delivers large molecules (biologics) subcutaneously and is designed for therapies that periodically require a certain total quantity of a formulated drug. Typical applications include proteins such as monoclonal antibodies (mAbs).

Market Dynamics: Drivers

Rise in incidences of chronic diseases & patients' shift toward advanced drug delivery systems

The demand for the global on-body drug delivery devices market is driven by multiple factors. One of the key factors is the rise in incidences of chronic diseases & patients' shift toward advanced drug delivery systems.

The increasing prevalence of chronic conditions such as diabetes, arthritis, hypertension, and cancer is a major factor driving the demand for on-body drug delivery devices. These devices enable more effective management of chronic diseases by allowing for precise dosing, improved adherence, and reduced variability in treatment response.

Patients are increasingly preferring on-body drug delivery devices due to their advantages over traditional drug delivery methods. These advantages include higher precision, lower dosing increments, home-use capabilities, automatic needle insertion and retraction, occlusion detection, and the use of standard glass cartridges. The ability to accurately target specific cells or tissues while minimizing side effects and increasing therapeutic efficacy is driving the adoption of these advanced drug delivery systems.

Moreover, key players in the industry strategies such as partnerships & collaborations, and product launches & approvals would propel this market growth. For instance, in March 2023, Stevanato Group S.p.A. announced its collaboration with Thermo Fisher Scientific to bring a fully integrated on-body delivery system platform for subcutaneous administration to the market.

Also, in April 2023, Medtronic announced the U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no finger sticks while in Smart Guard technology. This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections† to sugar levels every 5 minutes§ for both basal (background) and bolus (mealtime) insulin needs. The system provides insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meals.

Restraints

Factors such as the high costs of devices & treatment, the risk of needlestick injuries & patient discomfort, regulatory challenges, and lack of awareness among people, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global on-body drug delivery devices market is segmented based on device type, molecule type, application, distribution channels, and region.

The wearable injectors segment accounted for approximately 62.8% of the global on-body drug delivery devices market share

The wearable injectors segment is expected to hold the largest market share over the forecast period. Wearable injection systems are drug-delivery devices that adhere to the body, automatically delivering set doses to the patient at optimal times. Wearable injection systems represent the natural evolution of chronic disease management. As wearable injection systems have emerged in response to these conditions, so has a completely new set of challenges regarding device design and testing.

Moreover, key players in the industry product launches and approvals help to drive this segment growth in the market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG launched its UDENYCA on-body injector (OBI) utilizing the LTS Sorrel wearable drug delivery platform. UDENYCA (pegfilgrastim-cbqv) is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Also, in September 2023, Enable Injections, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse) for the subcutaneous delivery of EMPAVELI (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH). The EMPAVELI Injector is a compact, wearable injector designed to streamline the self-administration experience with minimal disruption to patients’ daily lives.

In addition, major players' innovative developments, investments, and mergers & acquisitions drive this segment's growth in the market. For instance, in January 2023, Eitan Medical opened a new manufacturing facility for a wearable drug delivery platform. The new manufacturing facility at its headquarters to support drug-delivery device production.

Similarly, in April 2023, LTS Lohmann acquired the Sorrel wearable injection device business headquartered in Netanya, Israel, a part of Eitan Medical Ltd.

Geographical Analysis

North America accounted for approximately 42.1% of the global on-body drug delivery devices market share

North America region is expected to hold the largest market share over the forecast period owing to the rising incidence of chronic diseases, demand for self-administration medications, and well-advanced healthcare infrastructure propelling the market growth in this region.

Moreover, a major number of key players' presence, technological advancements, and product launches & approvals drive the market growth. For instance, in February 2024, Tandem Diabetes Care, Inc. announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes. The company has begun taking orders and shipping to eligible customers in the United States.

Also, in October 2022, after five years and two unsuccessful attempts, scPharmaceuticals finally pushed its on-body infusor for congestive heart failure across the FDA finish line. With the approval, Furoscix becomes the first self-administered, subcutaneous loop diuretic for those with worsening HF.

The Food and Drug Administration (FDA) approved Furoscix (furosemide injection) for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

Market Segmentation

By Devices Type
• Wearable Injectors
• Infusion Pumps
• Others

By Molecules Type
• Small Molecule
• Large Molecule

By Application
• Cardiovascular Diseases
• Cancer
• Diabetes
• Auto-immune Disease
• Others

By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
The rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the on-body drug delivery devices market include Gerresheimer AG, NOVO Engineering, West Pharmaceutical Services, Inc., Enable Injections, Stevanato Group, LTS Lohmann Therapie-Systeme AG, BD, Coherus BioSciences, Inc., Tandem Diabetes Care, Inc, and Battelle among others.

Key Developments

 In January 2024, Aptar Digital Health and Gerresheimer developed an integrated cancer therapy solution. By connecting Aptar Digital Health’s proprietary SaMD platform with Gx SensAir, Gerresheimer’s on-body device for the subcutaneous delivery of large biologics molecules, this integrated solution is intended to improve overall treatment adherence and clinical outcomes.

 In December 2023, Stevanato Group introduced the new patented on-body delivery system Vertiva for several subcutaneous therapies. Designed to be adapted to different delivery profiles, the device facilitates the administration of biologics and small-molecule drugs.

Why Purchase the Report?
• To visualize the global on-body drug delivery devices market segmentation based on device type, molecule type, application, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the on-body drug delivery devices market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global on-body drug delivery devices market report would provide approximately 70 tables, 63 figures, and 184 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies